Navigation Links
Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
Date:1/7/2008

al worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations.

The risks included above are not exhaustive. The most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Renovis with the Securities and Exchange Commission contain additional factors that could impact the combined company's businesses and financial performance. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional information

Renovis has filed a Current Report on Form 8-K that includes as an exhibit the Agreement and Plan of Merger between Evotec and Renovis. Evotec has filed a Registration Statement on Form F-4 with the Securities and Exchange Commission in connection with the proposed merger. Evotec and Renovis expect to mail a joint proxy statement/prospectus, which will form part of the Registration Statement on Form F-4, to shareholders of Renovis in connection with the proposed merger. This document will contain important information about the merger and should be read before any decision is made with respect to the merger. Investors and stockholders will be able to obtain free copies of this document and any other documents filed or furnished by Evotec or Renovis through the website maintained by the Securities and Exchange Commission at http://www.sec.gov. Free copies of these documents may also be obtained from Evotec, by directing a request to Evotec's Investor Relations department at Schnackenburgallee 114, 22525 Hamburg, Germany, or from Renovis, by directing a request to Renovis' Investor
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... SAN DIEGO , May 16, 2013  The ... the Association of Bioscience Financial Officers (ABFO) 2013 National Conference, ... will be held May 28-31 at the Hilton San ... finishing touches on this year,s conference and want to ... opportunity to attend," said Brandi Roberts ...
(Date:5/16/2013)... Toronto, Canada (PRWEB) May 16, 2013 ... years and costs over one billion dollars. Despite this ... market. With stakes this high, is your clinical trial ... and deliver the best outcomes? , Dr. Frederic Sax, ... Quintiles, will discuss the use of data, information and ...
(Date:5/16/2013)... May 16, 2013 BioInformatics LLC New ... & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... of suppliers in the primary cells market continues to ... types are used most often, how satisfied scientists are ... size and anticipated growth rate. ,  , Additionally, ...
(Date:5/16/2013)... A number of residents in an apartment complex in ... abcactionnews.com, it was no thanks to the infestation of ... to the management and everyone else suffering from the pests ... public to try samples of it to prove it themselves ... 2013 determined that the complex invaded by bed ...
Breaking Biology Technology:Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 2Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 3
... for Pharmaceutical ... ... Codexis, Inc., a private,biotechnology company and leading developer of clean ... California Institute of Technology for preparing and identifying,drug metabolites (substances ...
... Colo., Aug. 29 AspenBio Pharma,Inc. (Nasdaq: APPY ... novel drugs and diagnostics for animals and humans,reported today ... annual Roth,Capital Partners New York Investor Conference to be ... investors are expected to attend the,conference, which will be ...
... of cardiovascular genetics ... ... GeneNews Limited (TSX: GEN),a company focused on developing patient-friendly blood-based ... or medical,condition, today announced that its co-founder and Chief Scientist ...
Cached Biology Technology:Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology 2AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference 2AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference 3GeneNews' Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book 2
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... investigating the interaction of a group of proteins in ... have identified a new target that could increase cell ... University,s School of Biochemistry and published in the ... could eventually lead to new therapies for stroke and ... work by the team which identified a protein, known ...
(Date:5/17/2013)... Societies for Experimental Biology (FASEB) released a new ... trends highlighting the devastating impact of sequestration on the ... follows a May 15th Senate Appropriations Committee hearing featuring ... the $1.6 billion cut the agency sustained in FY ... on the scientific community." , According to data ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2SUMO wrestling cells reveal new protective mechanism target for stroke 2
... sparking food and water shortages in the Middle East ... by an Australian climate scientist suggesting that rainfall will ... Recent projections from the Intergovernmental Panel on Climate Change ... Mediterranean would decline this century if global warming continues ...
... recovering drug abusers from relapsing, researchers at the University ... Barry Everitt, was able to reduce drug-seeking behaviours in ... learning and memory during the recall of drug-associated memories. ... Research Council, was reported in the 13 August issue ...
... the performance of different types of green roofs has ... at The University of Texas at Austin and suggests ... Interest in vegetated roofs has increased as water ... Yet the study of six different manufacturers, products found ...
Cached Biology News:Climate change may boost Middle East rainfall 2'Erasing' drug-associated memories may stop drug addiction relapses 2Green roofs differ in building cooling, water handling capabilities 2Green roofs differ in building cooling, water handling capabilities 3
WNV Core Antibody...
Rad51, N-terminal...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Biology Products: